Summary

The global hepatitis B infection market is expected to reach USD 18.21 billion by 2031 from USD 12.11 billion in 2023, growing at a CAGR of 5.2% in the forecast period of 2024 to 2031.
Market Segmentation:
Global Hepatitis B Infection Market Segmentation, By Type (Chronic and Acute), By treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery, By Countries (U.S., Canada and Mexico, China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Vietnam, New Zealand, Taiwan, Philippines, and rest of Asia-Pacific, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Denmark, Norway, Finland, Poland Turkey, and rest of Europe, South Africa, Saudi Arabia, Egypt, Kuwait, Qatar, U.A.E., Oman, Bahrain, and rest of Middle east and Africa, Brazil, Argentina, and rest of South America)- Industry Trends and Forecast to 2031

Overview of Global Hepatitis B infection Market Dynamics:

Driver

• Increasing prevalence of hepatitis B infections
Restraint

• Side effects and drug resistance

Opportunity

• Advanced research and development for clinical trials

Market Players:

The key market players operating in the global hepatitis B infection market are listed below:

• Gilead Sciences, Inc.
• GSK plc
• Dynavax Technologies
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb
• Merck Sharp and Dohme Corp.
• Novartis AG
• Arrowhead Pharmaceuticals Inc.
• Arbutus Biopharma
• Teva Pharmaceuticals, Inc.
• Zydus Pharmaceuticals
• Aurobindo Pharma
• Lupin Pharmaceuticals, Inc.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF GLOBAL HEPATITIS B INFECTION MARKET 23
1.4 MARKETS COVERED 26
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 CURRENCY AND PRICING 30
2.5 DBMR TRIPOD DATA VALIDATION MODEL 31
2.6 MULTIVARIATE MODELLING 34
2.7 THERAPEUTICS LIFELINE CURVE 35
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.9 DBMR MARKET POSITION GRID 37
2.10 VENDOR SHARE ANALYSIS 38
2.11 SECONDARY SOURCES 39
2.12 ASSUMPTIONS 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHT 46
4.1 PESTAL ANALYSIS 48
4.2 PORTER FIVE FORCES 49
5 GLOBAL HEPATITIS B INFECTION MARKET: REGULATIONS 50
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION 50
5.2 NORTH AMERICA REGULATORY SCENARIO 58
5.3 EUROPE REGULATORY SCENARIO 66
5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO 70
5.5 SOUTH AMERICA REGULATORY SCENARIO 75
6 PIPELINE ANALYSIS 80
7 EPIDEMILIOGY 91
8 MARKET OVERVIEW 93
8.1 DRIVERS 95
8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS 95
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS 96
8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B 97
8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION 98
8.2 RESTRAINTS 99
8.2.1 SIDE EFFECTS AND DRUG RESISTANCE 99
8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION 100
8.3 OPPORTUNITY 101
8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B 101
8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION 102
8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS 103
8.4 CHALLENGES 104
8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH 104
8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS 105
9 GLOBAL HEPATITIS B INFECTION MARKET, BY TYPE 106
9.1 OVERVIEW 107
9.2 CHRONIC 110
9.3 ACUTE 110
10 GLOBAL HEPATITIS B INFECTION MARKET, BY TREATMENT 111
10.1 OVERVIEW 112
10.2 VACCINE 115
10.2.1 HOSPITAL PHARMACIES 115
10.2.2 DRUGS STORES AND RETAIL PHARMACIES 115
10.2.3 ONLINE PHARMACIES 115
10.3 ANTIVIRAL DRUGS 116
10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF) 116
10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF) 116
10.3.3 ENTECAVIR 116
10.3.4 OTHERS 116
10.4 IMMUNE MODULATOR DRUGS 117
10.4.1 PEGYLATED INTERFERON 117
10.4.2 INTERFERON ALPHA 117
10.5 SURGERY 118
11 GLOBAL HEPATITIS B INFECTION MARKET, BY REGION 119
11.1 OVERVIEW 120
11.2 NORTH AMERICA 123
11.2.1 U.S 125
11.2.2 CANADA 127
11.2.3 MEXICO 129
11.3 SOUTH AMERICA 131
11.3.1 BRAZIL 133
11.3.2 ARGENTINA 135
11.3.3 REST OF SOUTH AMERICA 137
11.4 MIDDLE EAST AND AFRICA 138
11.4.1 SOUTH AFRICA 140
11.4.2 SAUDI ARABIA 142
11.4.3 EGYPT 144
11.4.4 KUWAIT 146
11.4.5 QATAR 148
11.4.6 U.A.E 150
11.4.7 OMAN 152
11.4.8 BAHRAIN 154
11.4.9 REST OF MIDDLE EAST AND AFRICA 156
11.5 ASIA-PACIFIC 157
11.5.1 CHINA 160
11.5.2 INDIA 162
11.5.3 INDONESIA 164
11.5.4 JAPAN 166
11.5.5 VIETNAM 168
11.5.6 PHILIPPINES 170
11.5.7 THAILAND 172
11.5.8 SOUTH KOREA 174
11.5.9 AUSTRALIA 176
11.5.10 SINGAPORE 178
11.5.11 MALAYSIA 180
11.5.12 NEW ZEALAND 182
11.5.13 TAIWAN 184
11.5.14 REST OF ASIA-PACIFIC 186
11.6 EUROPE 187
11.6.1 GERMANY 190
11.6.2 U.K 192
11.6.3 TURKEY 194
11.6.4 RUSSIA 196
11.6.5 SPAIN 198
11.6.6 ITALY 200
11.6.7 SWEDEN 202
11.6.8 BELGIUM 204
11.6.9 POLAND 206
11.6.10 FRANCE 208
11.6.11 SWITZERLAND 210
11.6.12 NETHERLANDS 212
11.6.13 NORWAY 214
11.6.14 DENMARK 216
11.6.15 FINLAND 218
11.6.16 REST OF EUROPE 220
12 GLOBAL HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE 221
12.1 COMPANY SHARE ANALYSIS: GLOBAL 221
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 222
12.3 COMPANY SHARE ANALYSIS: EUROPE 223
12.4 COMPANY SHARE ANALYSIS: ASIA - PACIFIC 224
13 SWOT ANALYSIS 225
14 COMPANY PROFILE 226
14.1 GILEAD SCIENCES, INC. 226
14.1.1 COMPANY SNAPSHOT 226
14.1.2 REVENUE ANALYSIS 226
14.1.3 COMPANY SHARE ANALYSIS 227
14.1.4 PRODUCT PORTFOLIO 227
14.1.5 RECENT DEVELOPMENT 227
14.2 GLAXOSMITHKLINE PLC 229
14.2.1 COMPANY SNAPSHOT 229
14.2.2 REVENUE ANALYSIS 229
14.2.3 COMPANY SHARE ANALYSIS 230
14.2.4 PRODUCT PORTFOLIO 230
14.2.5 RECENT DEVELOPMENT 230
14.3 DYNAVAX TECHNOLOGIES CORPORATION 232
14.3.1 COMPANY SNAPSHOT 232
14.3.2 REVENUE ANALYSIS 232
14.3.3 COMPANY SHARE ANALYSIS 233
14.3.4 PRODUCT PORTFOLIO 233
14.3.5 RECENT DEVELOPMENTS 233
14.4 F. HOFFMAN-LA ROCHE LTD. 235
14.4.1 COMPANY SNAPSHOT 235
14.4.2 REVENUE ANALYSIS 235
14.4.3 COMPANY SHARE ANALYSIS 236
14.4.4 PRODUCT PORTFOLIO 236
14.4.5 RECENT DEVELOPMENTS 236
14.5 BRISTOL-MYERS SQUIBB COMPANY 237
14.5.1 COMPANY SNAPSHOT 237
14.5.2 REVENUE ANALYSIS 237
14.5.3 COMPANY SHARE ANALYSIS 238
14.5.4 PRODUCT PORTFOLIO 238
14.5.5 RECENT DEVELOPMENTS 238
14.6 ARROWHEAD PHARMACEUTICALS, INC. 239
14.6.1 COMPANY SNAPSHOT 239
14.6.2 REVENUE ANALYSIS 239
14.6.3 PRODUCT PORTFOLIO 240
14.6.4 RECENT DEVELOPMENTS 240
14.7 ARBUTUS BIOPHARMA 241
14.7.1 COMPANY SNAPSHOT 241
14.7.2 REVENUE ANALYSIS 241
14.7.3 PRODUCT PORTFOLIO 242
14.7.4 RECENT UPDATES 242
14.8 AUROBINDO PHARMA 243
14.8.1 COMPANY SNAPSHOT 243
14.8.2 REVENUE ANALYSIS 243
14.8.3 PRODUCT PORTFOLIO 244
14.8.4 RECENT UPDATES 244
14.9 LUPIN PHARMACEUTICALS, INC. 245
14.9.1 COMPANY SNAPSHOT 245
14.9.2 PRODUCT PORTFOLIO 245
14.9.3 RECENT UPDATES 246
14.10 MERCK & CO., INC., 247
14.10.1 COMPANY SNAPSHOT 247
14.10.2 REVENUE ANALYSIS 247
14.10.3 PRODUCT PORTFOLIO 248
14.10.4 RECENT DEVELOPMENTS 248
14.11 NOVARTIS AG 249
14.11.1 COMPANY SNAPSHOT 249
14.11.2 REVENUE 249
14.11.3 PRODUCT PORTFOLIO 250
14.11.4 RECENT DEVELOPMENT 250
14.12 TEVA PHARMACEUTICAL INDUSTRIES 251
14.12.1 COMPANY SNAPSHOT 251
14.12.2 PRODUCT PORTFOLIO 251
14.12.3 RECENT DEVELOPMENTS 251
14.13 ZYDUS PHARMACEUTICALS, INC. 252
14.13.1 COMPANY SNAPSHOT 252
14.13.2 PRODUCT PORTFOLIO 252
14.13.3 REVENUE 253
14.13.4 RECENT DEVELOPMENT 253
15 QUESTIONNAIRE 254
16 RELATED REPORTS 256